Serum β-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO study

Journal of the American Society of Nephrology

Volumn 17, Issue 2, 2006, Pages 546-555

  Cheung, Alfred K ^a,q   Rocco, Michael V ^b   Yan, Guofen ^c   Leypoldt, John K ^a   Levin, Nathan W ^d   Greene, Tom ^c   Agodoa, Lawrence ^e   Bailey, James ^f   Beck, Gerald J ^c   Clark, William ^g,n   Levey, Andrew S ^h   Ornt, Daniel B ^i,o   Schulman, Gerald ^j   Schwab, Steven ^k,p   Teehan, Brendan ^l   Eknoyan, Garabed ^m  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d RENAL RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Baxter Corporation   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l LANKENAU HOSPITAL   (United States)

^m BAYLOR COLLEGE OF MEDICINE   (United States)

ⁿ Gambro   (United States)

^o CASE WESTERN RESERVE UNIVERSITY   (United States)

^p MEDICAL COLLEGE OF GEORGIA   (United States)

^q UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; CLEARANCE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; UREA BLOOD LEVEL;

EID: 33645460223     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005020132     Document Type: Article

References (32)

1. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux on mortality and morbidity in maintenance hemodialysis patients: Primary results of the HEMO study. N Engl J Med 347: 2010-2019, 2002
2. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G; for the HEMO Study Group: Effect of high-flux hemodialysis on clinical outcomes: Results of the HEMO Study. J Am Soc Nephrol 14: 3251-3263, 2003
3. Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, Levin NW, Schulman G, Eknoyan G: Design and statistical issues of the hemodialysis (HEMO) study. Control Clin Trials 21: 502-525, 2000
4. Eknoyan G, Levey AS, Beck GJ, Agodoa LY, Daugirdas JT, Kusek JW, Levin NW, Schulman G, for the HEMO Study Group: The Hemodialysis (HEMO) Study: Rationale for selection of interventions. Semin Dial 9: 24-33, 1996
5. Leypoldt JK, Cheung AK, Agodoa L, Daugirdas JT, Greene T, Keshaviah PR; for the Hemodialysis (HEMO) Study: Hemo dialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. Kidney Int 51: 2013-2017, 1997
6. Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, Levin NW, Leypoldt JK; the HEMO Study Group: Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. J Am Soc Nephrol 10: 117-127, 1999
7. Leypoldt JK, Cheung AK, Delmez JA, Gassman JJ, Levin NW, Lewis JAB, Lewis JL, Rocco MV; the HEMO Study Group: Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int 61: 266-275, 2002
8. Miskulin DC, Athienites NV, Yan G, Martin AA, Ornt DB, Kusek JW, Meyer KB, Levey AS; for the Hemodialysis (HEMO) Study Group: Comorbidity assessment using the index of coexistent disease in a multicenter clinical trial study. Kidney Int 60: 1498-1510, 2001
9. Cheung AK, Sarnak M, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS; for the HEMO Study Group: Cardiac diseases in maintenance patients: Results of the HEMO Study. Kidney Int 65: 2380-2389, 2004
10. Depner TA, Greene T, Daugirdas JT, Cheung AK, Gotch FA, Leypoldt JK; the Hemodialysis (HEMO) Study Group: Dialyzer performance in the HEMO Study: In vivo KoA and true blood flow determined from a model of cross-dialyzer urea extraction. ASAIO J 50: 85-93, 2004
11. Verbeke G, Molenberghs G: Linear Mixed Models for Longitudinal Data, New York, Springer-Verlag, 2000
12. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model, New York, Springer-Verlag, 2000
13. Bargman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 12: 2158-2162, 2001
14. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S; Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307-1320, 2002
15. Canaud B, Assounga A, Flavier JL, Slingeneyer A, Aznar R, Robinet-Levy M, Mion C: Beta-2 microglobulin serum levels in maintenance dialysis: What does it mean? Trans Am Soc Artif Intern Organs 34: 923-929, 1988
16. McCarthy JT, Williams AW, Johnson WJ: Serum beta2-microglobulin concentration in dialysis patients: Importance of intrinsic renal function. J Lab Clin Med 123: 495-505, 1994
17. van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J: Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 39: 1012-1029, 1991
18. Maeda K, Shinzato T, Ota T, Kobayakawa H, Takai I, Fujita Y, Morita H: Beta-2-microglobulin generation rate and clearance rate in maintenance hemodialysis patients. Nephron 56: 118-125, 1990
19. Nakao Y, Matsumoto H, Miyazaki T, Watanabe S, Masaoka T, Takatsuki K, Kishihara M, Kobayashi N, Hattori M, Fujita T: Genetic and clinical studies of serum beta 2-microglobulin levels in haematological malignancies. Clin Exp Immunol 46: 134-141, 1981
20. Mocroft A, Johnson MA, Sabin CA, Bofill M, Janossy G, Phillips AN: The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. Epidemiol Infect 118: 259-266, 1997
21. Arizono K, Nomura K, Motoyama T, Matsushita Y, Matsuoka K, Miyazu R, Takeshita H, Fukui H: Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif 22[Suppl 2]: 26-29, 2004
22. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52: 1096-1101, 1997
23. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W: A comparison of on-line hemodiafiltration and high-flux hemodialysis: A prospective clinical study. J Am Soc Nephrol 11: 2344-2350, 2000
24. Raj DS, Ouwendyk M, Francoeur R, Pierratos A: Beta(2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 15: 58-64, 2000
25. Hörl WH, Haag-Weber M, Georgopoulos A, Block LH: Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 87: 6353-6357, 1990
26. Haag-Weber M, Mai B, Horl WH: Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins. Nephrol Dial Transplant 9: 1769-1773, 1994
27. Pascual M, Schifferli JA: Adsorption of complement factor D by polyacrylonitrile dialysis membranes. Kidney Int 43: 903-911, 1993
28. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836-842, 1991
29. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox): Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63: 1934-1943, 2003
30. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Nephrol Dial Transplant 17[Suppl 7]: 16-31, 2002
31. Gorevic PD, Casey TT, Stone WJ, DiRaimondo CR, Prelli FC, Frangione B: Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest 76: 2425-2429, 1985
32. Gejyo F, Odani S, Yamada T, Honma N, Saito H, Suzuki Y, Nakagawa Y, Kobayashi H, Maruyama Y, Hirasawa Y, et al: Beta 2-microglobulin: A new form of amyloid protein associated with chronic hemodialysis. Kidney Int 30: 385-390, 1986